Mohammad Mobashir
About
Professional purpose and description: Dr. Mohammad Mobashir has received his M.Sc. in Molecular Lifesciences from Jacobs University (Constructor University) Bremen, Germany and Ph.D. Biochemistry from natural science faculty at the Institute of Molecular and Clinical Immunology, Otto-von-Guericke University, Magdeburg, Germany. He is a System biologist mainly interested in understanding complex human disease pathways, functions, biomarkers, and look for potential drug targets. Biological functions mainly arise as a result of the integration of multiple processes interacting across a range of spatio-temporal scales. The aim of his work is to develop theoretical approaches parallel to experimental validation and data integration which not only will address problems at specific scales and specific disease but also bridge scales at multiple levels in a computationally efficient and mathematically tractable way and finally, corelate and validate experimentally. My long term aim is to develop novel laboratory technique which could make smooth, easy, cost effective, and minimize time for the final report generation so that timely diagnosis could start for the individual patient.
Considering the therapies that have been so far created, majority of cancers remains difficult. While radiation treatment and aggressive surgical resection are commonly advised, opinions on second- or third-line salvage chemotherapy are divided. Therefore, it is essential to find new therapeutic alternatives for patients suffering from recurrence under specific protocols for specific types of cancer. Here, we want to examine by using our precision medicine methodology to cancer patient who has run out of conventional treatment choices. We will use systems pharmacological approach, computational chemistry, and integration of experimental information at different stages in the hybrid mathematical model leading to the prediction of phenotypic changes in our personalized therapeutic approach, which integrates in-vitro, in-vivo, and ex-vivo drug sensitivity testing (DST) to determine optimal individualized therapy for each patient. Finally, extend our published model with the experimental validation at different stages which we have published for the purpose of personalized medicine diagnostic approach.
Research
Dr. Mohammad Mobashir has received his M.Sc. in Molecular Lifesciences from Jacobs University (Constructor University) Bremen, Germany and Ph.D. Biochemistry from natural science faculty at the Institute of Molecular and Clinical Immunology, Otto-von-Guericke University, Magdeburg, Germany. He is a System biologist mainly interested in understanding complex human disease pathways, functions, biomarkers, and look for potential drug targets. Biological functions mainly arise as a result of the integration of multiple processes interacting across a range of spatio-temporal scales. The aim of his work is to develop theoretical approaches parallel to experimental validation and data integration which not only will address problems at specific scales and specific disease but also bridge scales at multiple levels in a computationally efficient and mathematically tractable way and finally, corelate and validate experimentally. My long term aim is to develop novel laboratory technique which could make smooth, easy, cost effective, and minimize time for the final report generation so that timely diagnosis could start for the individual patient.
Considering the therapies that have been so far created, majority of cancers remains difficult. While radiation treatment and aggressive surgical resection are commonly advised, opinions on second- or third-line salvage chemotherapy are divided. Therefore, it is essential to find new therapeutic alternatives for patients suffering from recurrence under specific protocols for specific types of cancer. Here, we want to examine by using our precision medicine methodology to cancer patient who has run out of conventional treatment choices. We will use systems pharmacological approach, computational chemistry, and integration of experimental information at different stages in the hybrid mathematical model leading to the prediction of phenotypic changes in our personalized therapeutic approach, which integrates in-vitro, in-vivo, and ex-vivo drug sensitivity testing (DST) to determine optimal individualized therapy for each patient. Finally, extend our published model with the experimental validation at different stages which we have published for the purpose of personalized medicine diagnostic approach.
Potential research area and ongoing projects:
Cancer--Stroma Crosstalk and tumor microenvironment
Ovarian cancer is a type of cancer with a wide range of histological, clinical, and molecular characteristics. Epithelial ovarian cancer is among the deadliest gynecologic cancer. Cancer cells and a variety of stromal cells make up the tissue of an ovarian tumor. There is mounting evidence that suggests stromal involvement is significant in the development and progression of ovarian cancer. Therefore, stroma-specific signaling pathways, stroma-derived components, and genetic alterations in the tumor stroma may offer special prospects for enhancing ovarian cancer diagnostics and therapeutic approach. One of the main elements of the tumor stroma that have shown supportive roles in tumor growth are cancer-associated fibroblasts (CAFs). We would like highlight the numerous signaling interactions between ovarian cancer cells and stromal cells in this planned proposal focusing on CAFs. We would also like to assess the role of signaling crosstalk in the course of ovarian cancer and describe strategies to target tumor-promoting signaling crosstalk and how these strategies can be used to ovarian cancer treatment.
The prognosis of patients with metastatic malignancies is still dismal because of therapy-resistant relapses, despite an initially positive response to treatment and the deployment of innovative targeted and immune-based therapeutic methods. Therefore, these patients urgently require improved treatment plans. We want to know: How may cancer- and stroma-dependent mechanisms of therapy-escape be used to more effectively eradicate heterogenous (micro)metastases that can support tumor evolution and recurrent growth?
Publications
- Mobashir M**, Schraven B, and Beyer T (2012) Simulated Evolution of Signal Transduction Networks. PLOS ONE 7(12): e50905. (IF - 3.752)
- Mobashir M**, Thati M, Isermann B, Beyer T and Schraven B (2014) Negative Interactions and Feedback Regulations are Required for Transient Cellular Response. Sci. Rep., 4, 3718 (IF - 4.996).
- Maqbool M, Mobashir M, Hoda N (2015) Pivotal Role of glycogen synthase kinase-3: A therapeutic target for Alzheimer’s disease. Eur Jour Med Chem (IF - 7.088).
- Gucciardo E, Mobashir M, and Lehti K (2016) Proactive for invasion: Reuse of matrix metalloproteinase for structural memory. J Cell Biology 213(1):11—13. (IF - 10.539).
- Jitendra Kumar, Poonam Meena, Anju Singh, Ehtesham Jameel, Mudasir Maqbool, Mohammad Mobashir, Ashutosh Shandilya, Manisha Tiwari, Nasimul Hoda, B. Jayaram (2016) Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies. Eur Jour Med Chem. 119:260-277 (IF - 7.088).
- Anju Singh, Mudasir Maqbool, Mohammad Mobashir, Nasimul Hoda (2017) Dihydroorotate dehydrogenase: A drug target for the development of antimalarials. Eur Jour Med Chem. 125:640-651 (IF - 7.088).
- Jitendra Kumar, Tarana Umar, Tasneem Kausar, Mohammad Mobashir, Shahid M Nayeem, Nasimul Hoda (2017). Identification of lead BAY60-7550 analogues as potential inhibitors that utilize the hydrophobic groove in PDE2A: a molecular dynamics simulation study. 7(23). Journal of Molecular Modeling. 2017. (IF: 2.172)
- Mobashir M and Mustafa S. (2020) LC--MS and docking profiling reveals potential difference between the pure and crude fucoidan metabolites. International Journal of Biological Macromolecules (IF - 8.025).
- Bhat SA, Ahmad SM, Ibeagha-Awemu EM, Mobashir M, Dar MA, Mumtaz T, Shah RA, Dar TA, Shabir N, Bhat HF, and Ganai NA (2020) Comparative milk proteome analysis of Kashmiri and Jersey cattle identifies differential expression of key proteins involved in immune system regulation and milk quality. BMC Genomics 21, 161 (2020). (IF—4.574).
- Mohammad Azhar Kamal, Mohiuddin Khan Warsi, Afnan Alnajeebi, Haytham A Ali, Nawal Helmi, Mohammad Asrar Izhari, Saad Mustafa, and Mobashir M** (2020) Gene expression profiling and clinical relevance to understand the role of hypoxia and immune signaling genes and pathways in breast cancer. Journal of Internal Medicine: Science & Art (IF - 0.12).
- Kumar PK, Kamal MA, Warsi MK, Alnajeebi A, Ali HA, Helmi N, Izhari MA, Mustafa S, and Mobashir M**. (2019) In-silico study reveals immunological signaling pathways, their genes, and potential herbal drug targets in ovarian cancer. Informatics In Medicine-Unlocked. (IF - 2.11).
- Praveen Kumar Posa Krishnamoorthy, Sekar Subasree, Udhayachandran Arthi, Mohammad Mobashir, Chirag Gowda, Prasanna DR (2020). T-cell Epitope-based Vaccine Design for Nipah Virus by Reverse Vaccinology Approach. Comb Chem High Throughput Screen. (IF - 1.714).
- Warsi MK, Kamal MA, Baeshen MN, Izhari MA, Firoz A, and Mobashir M** (2020) Comparative Study of Gene Expression Profiling Unravels Functions associated with Pathogenesis of Dengue Infection. Current Pharmaceutical Design (IF - 3.310).
- Mobashir M**, Trunnen SP, Izhari MA, Ashankyty IM, Helleday T, and Lehti K (2022). An approach for systems-level understanding of prostate cancer from high-throughput data integration to pathway modeling and simulation. (Cells 2022)(IF - 7.666).
- Eldakhakhny BM, Sadoun HA, Choudhary H, and Mobashir M** (2021) In-silico study of the immune systems associated genes in case of type-2 diabetes with Insulin action and resistance and in obesity. Frontiers in Endocrinology. 2021. (IF - 6.055).
- Alnajeebi AM, Alharbi HFA, Babteen NA, Mustafa S, and Helleday T, and Mobashir M**. Cancer signaling pathways crosstalk with DNA damage repair and therapeutic targets: Herbal drugs and nanoparticles. under review Seminars in Cancer Biology. 2021. (IF - 11.09).
- Manal Tashkandi and Mohammad Mobashir**. Evolution of type-2 diabetes ER protein processing gene regulatory network. Current Pharmaceutical Biotechnology. 2021 (accepted). (IF - 4.390).
- Nawal Helmi, Dalia Alammari, and Mohammad Mobashir** (2021). Role of potential COVID-19 immune system associated genes and the potential linkage with type-2 diabetes. (Accepted: 2021). Comb Chem High Throughput Screen. (IF - 1.714).
- HI Khouja, IM Ashankyty, LH Bajrai, PKP Kumar, MA Kamal, M Mobashir** (2022). Multi-staged gene expression profiling reveals potential genes and the critical pathways in kidney cancer. Sci Rep 12, 7240 (2022). https://doi.org/10.1038/s41598-022-11143-6. Sci. Rep. (IF - 4.996)
- H Choudhary, A Albukhari, M Mobashir, W Abdulaal. Study of APOBEC3B focused breast cancer pathways and the clinical relevance. (Under Review: 2021). Sci. Rep. (IF - 4.996).
- Leena Bajrai, Sayed Sartaj Sohrab, Thamir Abdulaziz A Alandijany, Mohammad Mobashir** (2021), Reyaz M, Mohammad Amjad Kamal, Ahmad Firoz, Shabana Parveen, and Esam Ibraheem Azhar**. Gene expression profiling during early acute febrile stage of dengue infection and its comparative analysis with Streptococcus pneumoniae infection. (Accepted: 2021). Front. Cell. Infect. Microbiol. (IF - 6.073).
- Manal Tashkandi and Mohammad Mobashir**. Evolution of type-2 diabetes ER protein processing gene regulatory network. (Accepted: 2021). Current Pharmaceutical Biotechnology. (IF - 4.390).
- Leena Hussein Bajrai, Sayed Sartaj Sohrab, Mohammad Mobashir**, Mohammad Amjad Kamal and Esam Ibraheem Azhar(2021). Understanding the role of potential pathways and its components including hypoxia and immune system in case of oral cancer. (September 2021). Sci. Rep. (IF - 4.996).
- Huwait EA and Mobashir M** (2022). Therapeutic role of Diosmin and human diseases. Biomedicines. (IF - 6.081).
- Encyclopedia entries: Mohammad Mobashir** and Etimad Huwait (2022) Critical properties of Diosmin. Encyclopedia. Available online: https://encyclopedia.pub/entry/22949.
- Sherif El-Kafrawy, Mai M El-Daly, Leena Bajrai, Thamir Abdulaziz A Alandijany, Arwa A Faizo, Mohammad Mobashir**, Sunbul S Ahmed, Sarfraz Ahmed, Shoaib Alam, Raja Jeet, Mohammad Amjad Kamal, and Esam Ibraheem Azhar (2022). Genomic profiling and network-level understanding uncover the potential genes and the pathways in hepatocellular carcinoma. (November 2022). Frontiers in Genetics. (IF - 4.599).
- Sarfraz Ahmed, Mohammad Mobashir, Lamya Ahmed Al-Keridis, Nawaf Alshammari, Mohd Adnan, Mohammad Abid and Imtaiyaz Hassan* (2022). A network-guided approach to discover phytochemical-based anticancer therapy targeting MARK4 for hepatocellular carcinoma. (Accepted: 2022). Frontiers in Oncology. (IF - 5.738)
- Nawal helmi, Dalia Alammari, and Mohammad Mobashir** (2022). The understanding of the potential linkage between COVID-19, type-2 diabetes, and cancer(s) could help in better drug-targets and therapeutics. (Accepted: 2022). Comb Chem High Throughput Screen. (IF - 1.714).
- Syed Tauqeer Anwer, Mohammad Mobashir**, Omer I. Fantoukh, Bushra Khan, Khalid Imtiyaz, Irshad H Naqvi, Moshahid Alam Rizvi** (2022). Synthesis of Silver Nano Particles Using Myricetin and the In-Vitro Assessment of Anti-colorectal Cancer Activity: in-silico Integration. (Accepted: 2022). International Journal of Molecular Sciences. (IF - 6.208).
- Sanaa Almowallad, Leena S. Alqahtani, and Mohammad Mobashir** (2022). NF--kB in signaling patterns and its temporal dynamics encode/decode human diseases. (Accepted: 2022). Life. (IF - 3.251).
- Mai El-Daly, Areej Alkhaldy, Maha M Alawi, Arwa A Faizo, Isra M Alsaady, Mohammad Amjad Kamal, Mohammad Mobashir**, Dolly Marothya, and Esam Ibraheem Azhar. Infection and inflammatory pathways their genes interplay as master regulators in encephalitis, Alzheimer's, coronary heart disease, and brain tumor: Potential herbal drug targets. (Accepted: 2022). Frontiers in Genetics (IF: 4.772).
- Mohammad Mobashir** (2022). The Understanding of the Potential Linkage between COVID-19, Type-2 Diabetes, and Cancer(s) Could Help in Better Drug Targets and Therapeutics. (Accepted: 2022). Comb Chem High Throughput Screen. (IF - 1.714)
- Salma Saddeek, Rehab Almassabi, and Mohammad Mobashir** (2022). Role of ZNF143 and its association with gene expression patterns, and non-coding mutations and its association with immune system in human breast cancer. Life. (IF - 3.251).
- Bushra Khan, Rowaid M Qahwaji, Mashael S Alfaifi, Mohammad Mobashir** (2024) Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage. Pharmaceutics 16 (6), 732. (IF - 4.9).
- Rowaid Qahwaji, Ibraheem Ashankyty, Naif S. Sannan, Mohannad S. Hazzazi, Ammar A. Basabrain, and Mohammad Mobashir** (2024) Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. Pharmaceuticals. 17(7), 940. (Accepted) (I.F. - 4.3).
2024
-
Qahwaji, Rowaid;
Ashankyty, Ibraheem;
Sannan, Naif S.;
Hazzazi, Mohannad S.;
Basabrain, Ammar A.;
Mobashir, Mohammad.
(2024)
Pharmacogenomics: A Genetic Approach to Drug Development and Therapy.
Pharmaceuticals
Academic literature review
Journal publications
-
Qahwaji, Rowaid;
Ashankyty, Ibraheem;
Sannan, Naif S.;
Hazzazi, Mohannad S.;
Basabrain, Ammar A.;
Mobashir, Mohammad.
(2024)
Pharmacogenomics: A Genetic Approach to Drug Development and Therapy.
Pharmaceuticals
Academic literature review